Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat

Kalliopi Zachou, Alexandros Sarantopoulos, Nikolaos K Gatselis, Themistoklis Vassiliadis, Stella Gabeta, Aggelos Stefos, Asterios Saitis, Panagiota Boura, George N Dalekos

Kalliopi Zachou, Nikolaos K Gatselis, Stella Gabeta, Aggelos Stefos, Asterios Saitis, George N Dalekos, Department of Medicine and Research Laboratory of Internal Medicine, School of Medicine, University of Thessaly, 41110 Larissa, Greece
Alexandros Sarantopoulos, Panagiota Boura, Clinical Immunology Unit, 2nd Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece
Themistoklis Vassiliadis, First Medical Propedeutic Department, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital Thessaloniki, 54636 Thessaloniki, Greece

Author contributions: Zachou K, Boura P and Dalekos GN had the original idea, designed and wrote the study protocol; Sarantopoulos A, Gatselis NK, Vassiliadis T and Gabeta S along with Zachou K and Dalekos GN made the laboratory work, collected and summarized the data as well as treated and followed the patients; Zachou K analyzed and interpreted the final data of the patients, and along with Boura P and Dalekos GN wrote the first draft of the manuscript; Zachou K, Vassiliadis T, Boura P and Dalekos GN made the final critical revision of the manuscript for important intellectual content; all authors approved the final version of the manuscript.

Correspondence to: George N Dalekos, MD, PhD, Professor, Head, Department of Medicine and Research Laboratory of Internal Medicine, School of Medicine, University of Thessaly, Biopolis, 41110 Larissa, Greece. dalekos@med.uth.gr
Telephone: +30-241-3502285 Fax: +30-241-3501557
Received: March 15, 2013 Revised: May 3, 2013 Accepted: June 8, 2013 Published online: July 27, 2013

Abstract

AIM: To present the characteristics and the course of a series of anti- hepatitis B virus core antibody (HBc) antibody positive patients, who experienced hepatitis B virus (HBV) reactivation after immunosuppression.

METHODS: We retrospectively evaluated in our tertiary centers the medical records of hepatitis B virus surface antigen (HBsAg) negative patients who suffered from HBV reactivation after chemotherapy or immunosuppression during a 3-year period (2009-2011). Accordingly, the clinical, laboratory and virological characteristics of 10 anti-HBc (+) anti-HBs (-)/HBsAg (-) and 4 anti-HBc (+)/antiHBs (+)/HBsAg (-) patients, who developed HBV reactivation after the initiation of chemotherapy or immunosuppressive treatment were analyzed. Quantitative determination of HBV DNA during reactivation was performed in all cases by a quantitative real time polymerase chain reaction kit (COBAS Taqman HBV Test; cut-off of detection: 6 IU/mL).

RESULTS: Twelve out of 14 patients were males; median age 74.5 years. In 71.4% of them the primary diagnosis was hematologic malignancy; 78.6% had received rituximab (R) as part of the immunosuppressive regimen. The median time from last chemotherapy schedule till HBV reactivation for 10 out of 11 patients who received R was 3 (range 2-17) mo. Three patients (21.4%) deteriorated, manifesting ascites and hepatic encephalopathy and 2 (14.3%) of them died due to liver failure.

CONCLUSION: HBsAg-negative anti-HBc antibody positive patients can develop HBV reactivation even 2 years after stopping immunosuppression, whereas prompt antiviral treatment on diagnosis of reactivation can be lifesaving.
undergoing chemotherapy or immunosuppression are potentially at risk of hepatitis B virus (HBV) reactivation which can be disastrous since it can lead to acute liver failure and death. In this report, we describe the characteristics and outcome in one of the larger series of patients ($n = 14$) with occult or resolved HBV who experienced HBV reactivation after receiving immunosuppression though they were initially HBV surface antigen-negative. Most of patients had received rituximab. We showed that these patients can develop severe HBV reactivation even 2 years after stopping immunosuppression, whereas prompt antiviral treatment on diagnosis of reactivation can be lifesaving.

Zachou K, Sarantopoulou A, Gatselis NK, Vassiliadi T, Gabela S, Stefos A, Saitis A, Bura P, Dalekos GN. Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat. *World J Hepatol* 2013; 5(7): 387-392 Available from: URL: http://www.wjgnet.com/1948-5182/full/v5/i7/387.htm DOI: http://dx.doi.org/10.4254/wjh.v5.i7.387

**INTRODUCTION**

Hepatitis B virus (HBV) is a common cause of liver disease, affecting more than 240 million people worldwide[10]. HBV carriers are traditionally identified by the detection of HBV surface antigen (HBsAg) in their blood. During the past 15 years with the availability of highly sensitive molecular methods, persistence of HBV genomes in HBsAg negative individuals has been clearly proven termed occult HBV infection (OBI).

Accordingly, OBI is defined by the presence of HBVDNA in the liver tissue or also in the serum of HBsAg negative individuals who are either anti-HBe antibodies (Abs) and/or anti-HBs Abs positivve or even have negative serological markers[2-4]. OBI is mainly related to a strong suppression of the viral activity in which the host’s immune surveillance is likely to play a major role. Therefore, patients with OBI undergoing strong immunosuppression are potentially at risk of HBV reactivation, a common phenomenon in HBsAg-positive hematological or oncological patients[5-10]. HBV reactivation has also been reported in patients with OBI treated with synthetic disease modifying antirheumatic drugs (DMARDs) and/or high-dose prednisolone for rheumatic diseases[10-13]. Especially in the era of targeted immune modulators (commonly referred to as biological response modifiers or “biologics”), which cause profound immunosuppression and are used in the treatment of immunological, inflammatory as well as hematological/oncological diseases, the risk becomes even greater[14].

The European Association for the Study of the Liver clinical practice guidelines for the management of chronic HBV infection in HBsAg-negative patients with positive anti-HBe Abs who receive chemotherapy and/or immunosuppression suggest HBVDNA determination in the serum and if undetectable, strict follow-up consisting of alanine aminotransferase (ALT) and HBVDNA testing[14]. Treatment with potent antivirals with high barrier to resistance (i.e., entecavir or tenofovir) is recommended upon confirmation of HBV reactivation before ALT elevation[15]. However, there are no surrogates or prognostic markers for impending HBV reactivation, making the follow-up of these patients difficult, since cost-effectiveness of serial and frequent HBVDNA testing has not been documented. For these reasons it is urgent to define the characteristics of these patients with OBI who experience HBV reactivation, when they receive immunosuppression as well as the features of the HBV reactivation itself.

Accordingly, in this case-study we describe the course of 14 patients with OBI who received intense immunosuppression with various biological or non-biological immune modifying agents for diverse pathological entities and experienced HBV reactivation.

**MATERIALS AND METHODS**

**Patients**

We retrospectively evaluated in our tertiary centers (Aristotle University Medical School and University of Thessaly Medical School) the medical records of HBsAg seronegative patients who suffered HBV reactivation after chemotherapy or immunosuppression during a 3-year period (2009-2011). Accordingly, we identified 14 patients with occult [anti-HBc (+)/anti-HBs (-)/HBsAg (-), $n = 10$] or resolved [anti-HBs (+)/antiHBc (+)/HBsAg (-), $n = 4$] HBV infection, who developed HBV reactivation after the initiation of chemotherapy or immunosuppressive treatment. The clinical, laboratory and virological characteristics of the patients were recorded. The mean follow-up of the patients from the time of the diagnosis of HBV reactivation was 8 (range 1-60) mo. Although there are no clear diagnostic criteria for HBV reactivation, we defined HBV reactivation as seroconversion from HBsAg negative to HBsAg positive with serum HBV DNA turning from negative to positive[14]. Quantitative determination of HBV DNA during reactivation was performed in all cases by a quantitative real time polymerase chain reaction kit (COBAS Taqman HBV Test; cut-off of detection: 6 IU/mL). All patients were anti-hepatitis C virus negative, anti-hepatitis A virus IgG positive, anti-HIV negative at baseline (before the initiation of immunosuppression) as well as at the time of HBV reactivation.

**RESULTS**

The 10 anti-HBc (+)/anti-HBs (-)/HBsAg (-) patients were all males, whereas 2 out of 4 anti-HBe (+)/anti-HBs (+)/HBsAg (-) patients were females. The median age at diagnosis of HBV reactivation was 74.5 (range 53-82) years, while the median age of the diagnosis of their primary disease and initiation of immunosuppression was 73 (range 49-80) years. The primary diagnosis
of 10 patients (71.4%) was hematologic malignancy: six suffered from non-Hodgkin lymphoma, one from Hodgkin lymphoma, one from Castleman’s disease, one from chronic lymphocytic leukemia and one from Waldenstrom’s macroglobulinemia (Table 1). Regarding the remaining 4 patients, 3 were diagnosed with rheumatological diseases (one with temporal arteritis, one with dermatomyositis and one with rheumatoid arthritis). Finally, the last patient had received kidney transplantation for chronic renal failure due to diabetes mellitus (Table 1). He was anti-HBc (+)/anti-HBs (-)/HBsAg (-) before kidney transplantation and he had received a cadaveric kidney from an HBsAg (-)/anti-HBc (-) donor.

Eleven out of 14 patients (78.6%) had received rituximab (R) as part of the immunosuppressive schedule regimen (Table 1). The patient suffering from Hodgkin lymphoma (patient 12) had sequentially received diverse schemes of chemotherapy, including combination with R and finally autologous hemopoietic stem cell transplantation (HSCT). The median time from the initiation of immunosuppression till HBV reactivation was 18.5 (range 6-48) mo. The median time from last chemotherapy cycle to HBV diagnosis was 17 (range 6-48) mo. The median time from last chemotherapy cycle to HBV reactivation was 22 (range 10-30) mo. The median time from last chemotherapy cycle to HBV reactivation was 18.5 (range 6-48) mo. The median time from last chemotherapy cycle to HBV reactivation was 22 (range 10-30) mo. The median time from last chemotherapy cycle to HBV reactivation was 18.5 (range 6-48) mo. The median time from last chemotherapy cycle to HBV reactivation was 22 (range 10-30) mo. The median time from last chemotherapy cycle to HBV reactivation was 18.5 (range 6-48) mo. The median time from last chemotherapy cycle to HBV reactivation was 22 (range 10-30) mo.

Table 1  Characteristics and outcome of the ten hepatitis B surface antigen (-)/anti-hepatitis B virus core antibody (+)/anti-hepatitis B virus surface antigen (-) patients (at baseline) who experienced hepatitis B virus reactivation after immunosuppressive therapy

| No. | Age, yr (at reactivation) | Sex | Disease | Type of IMS | Months from start of IMS to HBV reactivation | Months from last treatment cycle to diagnosis of HBV reactivation | HBV-DNA (IU/mL) at diagnosis of HBV reactivation | ALT/BLI/INR at diagnosis of HBV reactivation | Antiviral treatment | Serology at end of follow-up | Outcome |
|-----|--------------------------|-----|---------|-------------|---------------------------------------------|-------------------------------------------------------------|-------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|----------|
| 1   | 77 M NHL                  |     | C, Flud, R | 6            | 3                                            | > 17857000                                                 | 1472/3.22/1.3                                   | Tenofovir                                    | Anti-HBc (+)                                 | Alive, response1 |                       |
| 2   | 71 M NHL                  |     | CHOP-R    | 8            | 1                                            | 487934                                                     | 871/8.8/0.87                                    | Entecavir                                    | Anti-HBc (+)                                 | Liver-related death | Alive, response1 |
| 3   | 74 M NHL                  |     | C, Flud, R | 6            | 1                                            | 1310000                                                    | 73/0.7/0.97                                     | Tenofovir                                    | NA                                          | Alive, response1 |                       |
| 4   | 76 M NHL                  |     | R         | 24           | 1                                            | > 17857000                                                 | 374/0.44/1.22                                   | Entecavir                                    | No treatment due to spontaneous seroconversion | Anti-HBc (+)/anti-HBs (+) 22 IU/L |                       |
| 5   | 81 M NHL                  |     | CHOP-R    | 30           | 12                                           | 660570                                                     | 737/1.1/1.37                                   | Tenofovir                                    | Anti-HBc (+)                                 | NA                                          | Alive, response1 |
| 6   | 78 M Castleman’s disease |     | P, R      | 12           | 1 (from last R cycle)                        | 4228720                                                    | 1536/15.8/1.03                                  | Lamivudine                                   | Anti-HBc (+), anti-HBs (+) 189 IU/L | Non-liver related death | Alive, response1 |
| 7   | 82 M CLL                  |     | Chl, R, C | 22           | 17 (from last R cycle)                       | > 17857000                                                 | 3440/20.8/1.7                                   | Tenofovir                                    | Anti-HBc (+)/anti-HBs (+), HBsAg (+) | Alive, response1 |                       |
| 8   | 72 M Temporal arteritis   |     | P, MTX    | 6            | 0                                            | > 17857000                                                 | 308/0.63/1.03                                   | Tenofovir                                    | NA                                          | Alive, response1 |                       |
| 9   | 75 M Dermatomyositis      |     | P, MTX, AZA, Cyc | 15        | 0                                            | 126092                                                     | 657/1.47/0.86                                   | Entecavir                                    | Anti-HBc (+)/anti-HBc (+), HBsAg (+) | Alive, response1 |                       |
| 10  | 53 M Kidney transplantation |   | P, Cyc, Myc | 48           | 0                                            | > 17857000                                                 | 28/0.96/0.98                                   | Entecavir                                    | Anti-HBc (+), anti-HBc (+), HBsAg (+) | Alive, response1 |                       |
| 11  | 73 F NHL                  |     | CHOP-R    | 9            | 4                                            | 127000                                                     | 614/1.2/1.12                                    | Lamivudine                                   | Anti-HBc (+), anti-HBs (+), HBsAg (+) | Alive, response1 |                       |
| 12  | 68 M HL                   |     | ABVD, CHOP-R, DHAP, HSC transplantations, BEAM | 28           | 16                                           | > 17857000                                                 | 49/1.1/1.01                                    | Tenofovir                                    | Anti-HBc (+)/anti-HBs (+) 180 IU/L | Liver-related death | Alive, response1 |
| 13  | 77 M Waldenström’s |     | C, R      | 36           | 3 (from last R cycle)                        | > 17857000                                                 | 2500/19/1.19                                   | Tenofovir                                    | Anti-HBc (+)/anti-HBs (+) 570 IU/mL | Alive, response1 |                       |
| 14  | 64 F RA                   |     | MTX, R    | 24           | 2 (from last R cycle)                        | > 17857000                                                 | 72/1.02/0.96                                   | Entecavir                                    | NA                                          | Alive, response1 |                       |

1Clinical and biochemical response to antiviral treatment. HBV: Hepatitis B virus; HBC: Hepatitis B virus core antibody; HBsAg: Hepatitis B virus surface antigen; F: Female; M: Male; NHL: Non-Hodgkin lymphoma; CLL: Chronic lymphocytic leukemia; IMS: Immunosuppression; C: Cyclophosphamide; Flud: Fludarabin; R: Rituximab; CHOP-R: Cyclophosphamide Doxorubicin Vincristine Prednisone-Rednizolon; Chl: Chlorambucil; MTX: Methotrexate; AZA: Azathioprine; Cyc: Cyclophosphamide; Myc: Mycophenolate. NA: Not applicable.
nosed with HBV reactivation 16 mo after HSCT. The remaining 3 patients experienced reactivation while on immunosuppression containing corticosteroids (Table 1).

The viral load during the diagnosis of HBV reactivation was high in 50% of the patients (above 17857000 IU/ml). The median viral load in the sera of the remaining patients was 574252 IU/ml (range 12700-4228720 IU/ml). The median maximum ALT, aspartate aminotransferase, bilirubin and INR levels during reactivation was 635.5 IU/ml (range 28-3440 IU/ml), 339 IU/ml (range 24-2306 IU/ml), 1.47 mg/dL (range 1-20.8 mg/dL) and 1.075 (range 0.86-1.7), respectively. However, all our patients were asymptomatic during reactivation and were diagnosed in routine laboratory testing.

All but one patients received antiviral treatment with nucleos(t)ide analogues immediately after the diagnosis of HBV reactivation (Table 1). Actually, the median time from the documentation of transaminase rise until treatment initiation was 15 (range 0-180) d. Patient 5 had already achieved seroconversion (disappearance of HBsAg and development of anti-HBs Abs) at diagnosis of HBV reactivation and for this reason he did not receive any treatment.

The HBV serological markers of 10 patients who were tested at the end of follow-up, are shown in Table 1. In more detail, 4 (40%) patients seroconverted to anti-HBs Abs after a median of 10.5 (range 3-60) mo. Three (30%) patients remained HBsAg (+)/HBeAg (+) after 24 mo the two and after 1-mo the third whereas the remaining 3 (30%) patients were anti-HBe (+)/anti-HBs (+) at the end of follow-up (after 1, 7 and 26 mo, respectively).

Regarding the outcome, 3 patients (21.4%) deteriorated, manifesting ascites and hepatic encephalopathy and 2 (14.3%) of them died due to liver failure. The third died of a non-liver related cause, 60 mo after the diagnosis of HBV reactivation.

DISCUSSION

The natural course of chronic HBV infection is determined by the interplay between virus replication and the host’s immune response[17]. In case of OBI, a long-term persistence in the nuclei of the hepatocytes of the HBV covalently-closed-circular DNA (cccDNA) supports its molecular basis[18]. In parallel, there is a strong suppression of the viral activity by the host’s immune surveillance, which is likely to be the factor of utmost importance. However, this state of suppression of viral replication and gene expression may be discontinued by any kind of immunosuppression, leading to the development of a typical hepatitis B that often has a severe, even fulminant, clinical course.

To the best of our knowledge, this is one of the larger series of patients with OBI or resolved HBV infection who experienced HBV reactivation after receiving immunosuppression. The incidence of such a clinical adversity varies in the literature, depending on the population studied or the immunosuppressive regimen used. Among patients with OBI and malignancies the reported incidence fluctuates between 2.7%-6%, for conventional regimens and 25%-50% when R is used. In patients with rheumatologic diseases the incidence of HBV reactivation in resolved infection is rather lower ranging from 2.2%-28% to 5.2%-41%. However, in the later study[18], when only patients treated with biological agents were taken into account, the incidence raised to 11.5%. Our series confirms two points: first the vast majority (71.4%) of the patients were diagnosed with hematologic malignancy and second approximately 80% of the patients had received R, sometime during their course.

R is a monoclonal antibody directed against the CD20 antigen expressed on the surface of normal and malignant B lymphocytes causing apoptosis. B cell plays a key role in the multiple immune responses against HBV: besides the production of neutralizing antibodies, it is an antigen presenting cell and enhances the cytotoxic response of CD8 T lymphocytes. Therefore, its destruction favors dramatically HBV replication. Our series is in accordance with the finding that R is a HBV reactivation risk factor even greater than corticosteroids, since in a series of patients with lymphoma treated with chemotherapy (CMT), the only significant difference between the reactivation group with resolved hepatitis and the group without reactivation was treatment with R[5]. In addition, three recent reports, including a meta-analysis of 184 case reports, have demonstrated that R containing regiments significantly increased the risk of HBV reactivation in OBI patients by five-fold compared to non-R regiments[5,19,20].

Since by definition CMT/immunosuppression decreases the ability of the immune system to respond, a period of time is necessary for immune reconstitution and subsequent attack on the liver, where a massive replication of HBV has taken place due to lack of “surveillance”[17]. For this reason, HBV reactivation often manifests in periods between cycles of CMT/immunosuppressive treatment or at the end of therapy after the recovery of the host immune system[21]. Therefore, in HBsAg carriers the time between last CMT cycle and HBV reactivation detection is variable: from 1-36 mo, usually ranging between 1 and 4 mo[21]. From the present study, it seems that the same is true also for resolved HBV infection, since the median time from last cycle to reactivation was 3 mo, although with wide variation from 2 to 17 mo. Therefore, it is crucial to closely follow-up patients with OBI after stopping immunosuppression, especially when they have received R, for at least 2 years. In addition, patients who are in continuous immunosuppression containing corticosteroids without R in the regimen, must be considered as vulnerable as those receiving cycles of CMT, since especially after corticosteroid tapering- they can develop HBV reactivation at any time even after 4 years, as happened with patient 10 who had received kidney transplantation.

The clinical course of HBV reactivation usually begins with HBV replication, during which serum HBVDNA levels increase and in a second phase hepatitis occurs (2-3
wk after HBVDNA elevation) characterized by increase of transaminases and, occasionally appearance of symptoms such as fatigue, malaise and jaundice.[22] However, the reactivation can also present with fulminant hepatitis which intimates a poor prognosis. In the present cohort, 1/5 of the patients manifested fulminant liver failure and 14% died. In a recent meta-analysis of case reports and case series of R associated HBV reactivation in lymphopoietic diseases[28], the fulminant liver failure rate and, as a consequence, the liver related mortality rate among the HBcAb (+)/HBsAg (−) cases was between 20% and 50%. The low mortality in our present case series could be attributed to the immediate initiation (within a median of 15d of antiviral treatment after transaminase elevation. In many circumstances, this is not the case, since these patients are, frequently, not recognized as a reactivation high-risk group, leading to an underestimation of hepatitis due to HBV.[b9].

The vast majority of our patients received tenofovir or entecavir, drugs with high barrier to resistance. This can be justified by considering that current guidelines[10] recommend therapy with nucleoside analogue for at least 6-12 mo after discontinuation of chemotherapy and patients with hematological malignancies receive long term therapeutic regimens so they will probably demand long term use of antiviral treatment with the risk to develop treatment-resistant HBV variants if treated with lamivudine.

Male sex has been reported to be a significant factor associated with the risk of developing HBV reactivation in HBsAg (−) cancer patients on chemotherapy.[24,25] Interestingly, 12 out of 14 patients in the present study were male, which is in accordance with previous studies[19] on OBI patients. Male sex along with old age (median age at reactivation 74 years) could define two characteristics of OBI patients who reactivated after immunosuppression. It is unfortunate that blood samples were not available in our patients, for HBVDNA testing at baseline before the institution of immunosuppression, since in a recent study[26], HBVDNA testing had a 90% ability to forecast persistent HBsAg negativity in HBV DNA negative patients showing that highly sensitive serum HBVDNA testing had better performance than serological tests in predicting HBsAg reapparance.

In conclusion, patients with OBI who develop HBV reactivation after immunosuppression are more likely to have received R as a component of their treatment for their underlying disease, are more frequently older males and they can experience hepatitis due to HBV reactivation even 2 years after stopping the immunosuppressive therapy. Immediate start of antiviral treatment with potent antivirals after transaminase elevation and diagnosis of HBV reactivation with HBVDNA testing is of utmost importance in order to prevent deterioration and fulminant liver failure leading to lethal outcome. Two strategies could be adopted in order to prevent HBV reactivation in OBI patients: baseline and serial HBVDNA testing during and at least one year after the end of immunosuppressive treatment[23] or pre-emptive treatment with antivirals in all anti-HBc Abs (+) patients with or without resolved infection particularly when R is used. However, clinical evidence to date is not informative for determining optimal frequency and duration of such HBVDNA monitoring, whereas, concerning pre-emptive treatment, there are issues such as drug resistance and cost effectiveness, which also need to be addressed. Therefore, further studies to better define the characteristics of OBI patients who are “prone” to reactivation after receiving immunosuppression are needed, while in parallel establishment of new, precise guidelines on how to handle these patients seems to be extremely urgent considering the high mortality rate of a disease which can be effectively managed.
Zachou K et al. HBV reactivation in HBsAg-negative patients.

4 Georgiadou SP, Zachou K, Rigopoulou E, Liaskos C, Mina P, Gerovasili F, Makri E, Dalekos GN. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases. J Viral Hepat 2004; 11: 358-365 [PMID: 15230859]

5 Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68 [PMID: 16831590]

6 Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188 [PMID: 2198820]

7 Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, Kim TY, Sohn JH, Lee HS. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol 2010; 37: 346-350 [PMID: 20008922 DOI: 10.3899/jrheum.090436]

8 Caporali R, Bobblio-Palavaccini F, Atzeni F, Sakellariou G, Capiroli M, Montecucco C, Sarzi-Puttini P. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken) 2010; 62: 749-754 [PMID: 20535784 DOI: 10.1002/acr.20310]

9 Charpin C, Guis S, Colson P, Borentain P, Mattéi JP, Alcanzar P, Balandraud N, Thomachot B, Roudier J, Gérolami R. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009; 11: R179 [PMID: 19941642 DOI: 10.1186/ar2868]

10 Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papathodoridis GV, Manolakopoulos S, Koskinas J, Maresis EK, Archimandritis AI. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010; 69: 1352-1355 [PMID: 20472596 DOI: 10.1136/ard.2009.127233]

11 Urata Y, Uesato R, Tanaka D, Kawatari K, Nitobe T, Nakamura Y, Motomura Y. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 2011; 21: 16-23 [PMID: 20668905]

12 Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa K, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N. Reactivation of hepatitis B virus replication in rheumatoid arthritis patients who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011; 46: 556-564 [PMID: 21246383 DOI: 10.1007/s00535-010-0367-5]

13 Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol 2011; 21: 621-627 [PMID: 21528424 DOI: 10.1007/s10165-011-0458-z]

14 Zachou K, Dalekos GN. Hepatitis B re-activation with rituximab therapy: treat the patient not the disease. Liver Int 2011; 31: 277-279 [PMID: 21281426 DOI: 10.1111/j.1478-3231.2011.02452.x]

15 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]

16 Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113: 3147-3153 [PMID: 19144986 DOI: 10.1182/blood-2008-10-163493]

17 Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-1108 [PMID: 8837608]

18 Levero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of ccDNA function in hepatitis B virus infection. J Hepatol 2009; 51: 581-592 [PMID: 19616338 DOI: 10.1016/j.jhep.2009.05.022]

19 Yeow W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KJ, Mok TS, Chan PK. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B virus undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611 [PMID: 19075267 DOI: 10.1200/JCO.2008.18.0182]

20 Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, Chiu BC, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011; 22: 1170-1180 [PMID: 21156063 DOI: 10.1093/annonc/mdq583]

21 Wursthorn K, Wedemeyer H, Manns MP. Managing HBV in patients with impaired immunity. Gut 2010; 59: 1430-1445 [PMID: 20525688 DOI: 10.1136/gut.2009.195834]

22 Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapeutic or immunosuppressive therapy. World J Gastroenterol 2011; 17: 1531-1537 [PMID: 21472116 DOI: 10.3748/wjg.v17.i12]

23 Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90: 13-23 [PMID: 19544079 DOI: 10.1007/s12185-009-0359-5]

24 Lau GK, Lee CK, Liang R. Hepatitis B virus infection and bone marrow transplantation. Crit Rev Oncol Hematol 1999; 32: 233-251 [PMID: 10522191]

25 Yeow W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307 [PMID: 11055239]

26 Ferraro D, Pizzillo P, Di Marco V, Vultaggio A, Iannitto E, Venezia G, Craxi A, Di Stefano R. Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable? Liver Int 2009; 29: 1171-1177 [PMID: 19602139 DOI: 10.1111/j.1478-3231.2009.02071.x]

P-Reviewers Calabrese LH, Khattab MA S-Editor Zhai HH L-Editor A E-Editor LJY
